CD274 and melanoma: Preclinical models show that intratumoral I3A (150–200 μM) delivered via engineered probiotics (e.g., L. reuteri overexpressing Trp 2,3-dioxygenase) enhances anti-PD-L1 efficacy in melanoma (113).